{"id":"pd-1-monoclonal-antibody","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL2109418","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 is an immune checkpoint receptor that, when engaged by its ligands (PD-L1 or PD-L2), suppresses T cell activation and allows tumors to evade immune surveillance. By blocking this interaction, the antibody releases the brakes on the immune system, enabling T cells to recognize and attack cancer cells. This mechanism is fundamental to checkpoint inhibitor immunotherapy.","oneSentence":"This monoclonal antibody binds to PD-1 on T cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:59:59.477Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (specific approved indications not definitively established for this institutional candidate)"}]},"trialDetails":[{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT06594991","phase":"PHASE2","title":"A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-10","conditions":"Advanced Melanoma","enrollment":88},{"nctId":"NCT03816358","phase":"PHASE1","title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-09","conditions":"Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":74},{"nctId":"NCT04785820","phase":"PHASE2","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":190},{"nctId":"NCT06425926","phase":"PHASE1, PHASE2","title":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Georgiamune Inc","startDate":"2024-05-09","conditions":"Melanoma Stage IV, Solid Tumor","enrollment":117},{"nctId":"NCT05763004","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunOs Therapeutics AG","startDate":"2023-03-15","conditions":"Solid Tumor, Adult","enrollment":140},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT07422363","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-28","conditions":"Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma","enrollment":30},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT05982522","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Solid Tumors","status":"WITHDRAWN","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2025-08-13","conditions":"Solid Tumor","enrollment":""},{"nctId":"NCT05287113","phase":"PHASE2","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences International Sàrl","startDate":"2022-11-14","conditions":"Head and Neck Cancer","enrollment":176},{"nctId":"NCT04234113","phase":"PHASE1","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2019-06-13","conditions":"Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer","enrollment":115},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT03361852","phase":"PHASE1","title":"Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-03-14","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT07490990","phase":"","title":"A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-06","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT07488533","phase":"PHASE2","title":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT03521830","phase":"PHASE2","title":"Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-27","conditions":"Basal Cell Carcinoma","enrollment":57},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT05661955","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-09","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma","enrollment":113},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT07277439","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-16","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT07484022","phase":"PHASE1","title":"Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Generate Biomedicines","startDate":"2026-03","conditions":"Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma","enrollment":37},{"nctId":"NCT05981703","phase":"PHASE1","title":"A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-09-21","conditions":"Advanced Solid Tumor, Solid Tumor","enrollment":217},{"nctId":"NCT04181788","phase":"PHASE1, PHASE2","title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-03-18","conditions":"Advanced Malignancies, Non-small-cell Lung Cancer","enrollment":155},{"nctId":"NCT05689853","phase":"PHASE1, PHASE2","title":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-04-14","conditions":"Solid Tumor, Adult","enrollment":87},{"nctId":"NCT07479485","phase":"PHASE1, PHASE2","title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","status":"NOT_YET_RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2026-04","conditions":"Hepatocellular Carcinoma","enrollment":160},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05187182","phase":"PHASE1","title":"CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-06-02","conditions":"Gastric Cancer, Esophageal Cancer, Stomach Cancer","enrollment":42},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT03585465","phase":"PHASE1, PHASE2","title":"Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-26","conditions":"Childhood Solid Tumor","enrollment":63},{"nctId":"NCT04375384","phase":"PHASE2","title":"Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":"Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma","enrollment":38},{"nctId":"NCT03799445","phase":"PHASE2","title":"Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-25","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT05738694","phase":"PHASE3","title":"Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma","status":"RECRUITING","sponsor":"ZHOU FANGJIAN","startDate":"2023-04-19","conditions":"Renal Cell Carcinoma, Neoadjuvant","enrollment":298},{"nctId":"NCT02504372","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":1177},{"nctId":"NCT07476326","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-06-01","conditions":"Melanoma","enrollment":120},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT07474064","phase":"PHASE2","title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","status":"NOT_YET_RECRUITING","sponsor":"chenxu","startDate":"2026-03-26","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":146},{"nctId":"NCT02998268","phase":"PHASE2","title":"Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-03-07","conditions":"Esophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT07472153","phase":"PHASE2, PHASE3","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer","enrollment":120},{"nctId":"NCT07252739","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-19","conditions":"Malignant Neoplasm","enrollment":130},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":21},{"nctId":"NCT03607890","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-16","conditions":"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors","enrollment":38},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT07469306","phase":"PHASE2","title":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-08-10","conditions":"Locally Advanced Rectal Cancer","enrollment":130},{"nctId":"NCT04301778","phase":"PHASE2","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-24","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":5},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05935098","phase":"PHASE1","title":"BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2023-08-21","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor","enrollment":99},{"nctId":"NCT07471165","phase":"PHASE2","title":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Locally Advanced Perihilar Cholangiocarcinoma","enrollment":25},{"nctId":"NCT06449209","phase":"PHASE2","title":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-05","conditions":"Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer","enrollment":110},{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT02908906","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-11-21","conditions":"Neoplasms","enrollment":413},{"nctId":"NCT05401786","phase":"PHASE2","title":"Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2023-01-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":54},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT07466303","phase":"PHASE2","title":"Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-25","conditions":"Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer","enrollment":84},{"nctId":"NCT05098210","phase":"PHASE1","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-06-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma","enrollment":25},{"nctId":"NCT07391670","phase":"PHASE1","title":"A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-31","conditions":"Solid Tumours","enrollment":40},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT07090148","phase":"PHASE1","title":"Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-03-03","conditions":"Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer","enrollment":14},{"nctId":"NCT06981325","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-08-07","conditions":"Basal Cell Carcinoma (BCC), First Line Treatment","enrollment":34},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT04166383","phase":"PHASE2","title":"VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-09","conditions":"Metastatic Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":14},{"nctId":"NCT06821503","phase":"PHASE1, PHASE2","title":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-11","conditions":"Advanced Pancreatic Cancer","enrollment":72},{"nctId":"NCT05926960","phase":"PHASE2","title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-06-13","conditions":"Melanoma","enrollment":38},{"nctId":"NCT05116189","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-13","conditions":"Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms","enrollment":643},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT07457177","phase":"PHASE2","title":"Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL","status":"NOT_YET_RECRUITING","sponsor":"LIANG WANG","startDate":"2026-02-10","conditions":"NK T-Cell Lymphoma","enrollment":40},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT04736173","phase":"PHASE2","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2021-02-08","conditions":"Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer","enrollment":169},{"nctId":"NCT07453342","phase":"","title":"Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-01","conditions":"Immune-Related Adverse Events","enrollment":500},{"nctId":"NCT05731726","phase":"PHASE2","title":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-02-22","conditions":"pMMR, MSS, MSI-L","enrollment":50},{"nctId":"NCT06857279","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-22","conditions":"Carcinoma of Head and/or Neck","enrollment":167},{"nctId":"NCT07452003","phase":"NA","title":"An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-03","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07205731","phase":"PHASE2","title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10-07","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":95},{"nctId":"NCT02362594","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-16","conditions":"Melanoma","enrollment":1019},{"nctId":"NCT06114940","phase":"PHASE2","title":"Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)","status":"TERMINATED","sponsor":"Jinling Hospital, China","startDate":"2022-12-20","conditions":"Renal Cell Carcinoma (RCC)","enrollment":17},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT06826768","phase":"PHASE1","title":"A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-09","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07174908","phase":"PHASE3","title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2025-09-10","conditions":"Non-Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07444437","phase":"PHASE2","title":"LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2026-02-26","conditions":"Non-Small Cell Lung Cancer","enrollment":45},{"nctId":"NCT07436390","phase":"NA","title":"IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2024-03-31","conditions":"Metastatic Melanoma, Malignant Melanoma, Skin Cancer","enrollment":132},{"nctId":"NCT03514017","phase":"PHASE2","title":"Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-05-31","conditions":"Chronic Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":72}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BONE MARROW FAILURE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"GASTROINTESTINAL TOXICITY"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sintilimab","Toripalimab","Tislelizumab","PD-1","MW11 injection"],"phase":"marketed","status":"active","brandName":"PD-1 Monoclonal Antibody","genericName":"PD-1 Monoclonal Antibody","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This monoclonal antibody binds to PD-1 on T cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses. Used for Various solid tumors and hematologic malignancies (specific approved indications not definitively established for this institutional candidate).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}